Inger Nijhof

DR.

Medical Specialist, AII - Immunology Affiliatie VU Medical Specialist, CCA - Cancer Treatment and quality of life Medical Specialist, CCA - Cancer biology and immunology Research Associate, Hematology

Specialization

Focus of research

Latest publications

Assessing frailty in myeloma: The pursuit of simplicity may sacrifice precision of predicting clinical outcomes
Groen, K., Smits, F., Nasserinejad, K., Levin, M-D., Regelink, J. C., Timmers, G-J., de Waal, E. G. M., Westerman, M., Velders, G. A., de Heer, K., Leys, R. B. L., van Kampen, R. J. W., Stege, C. A. M., Seefat, M. R., Nijhof, I. S., van der Spek, E., Klein, S. K., van de Donk, N. W. C. J., Ypma, P. F. & Zweegman, S., 1 Jul 2024, In: HemaSphere. 8, 7, e85.
Research output: Contribution to journal › Comment/Letter to the editor › Academic
Additional booster doses in patients with chronic lymphocytic leukemia induce humoral and cellular immune responses to SARS-CoV-2 similar to natural infection regardless ongoing treatments: A study by ERIC, the European Research Initiative on CLL
Campanella, A., Capasso, A., Heltai, S., Taccetti, C., Albi, E., Herishanu, Y., Haggenburg, S., Chatzikonstantinou, T., Doubek, M., Kättström, M., Giannopoulos, K., Simkovic, M., Moreno, C., Massaia, M., Bumbea, H., Alshemmari, S., Ranghetti, P., Perotta, E., Martini, F., Sant'Antonio, E., & 24 othersColia, M., Combi, C., Levi, S., Kater, A. P., Hazenberg, M., Nijhof, I. S., Hofsink, Q., Demosthenous, C., Kotaskova, J., Zaleska, J., Vrbacky, F., Raya, A. M., Bisogno, D., Tripoli, I. E., Popov, V. M., Roman, V., Stavroyianni, N., Karypidou, M., Scarano, E., Locatelli, M., Frenquelli, M., Scarfò, L., Stamatopoulos, K. & Ghia, P., Apr 2024, In: American journal of hematology. 99, 4, p. 745-750 6 p.
Research output: Contribution to journal › Letter › Academic › peer-review
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Sonneveld, P., Dimopoulos, M. A., Boccadoro, M., Quach, H., Ho, P. J., Beksac, M., Hulin, C., Antonioli, E., Leleu, X., Mangiacavalli, S., Perrot, A., Cavo, M., Belotti, A., Broijl, A., Gay, F., Mina, R., Nijhof, I. S., van de Donk, N. W. C. J., Katodritou, E., Schjesvold, F., & 23 othersSureda Balari, A., Rosiñol, L., Delforge, M., Roeloffzen, W., Silzle, T., Vangsted, A., Einsele, H., Spencer, A., Hajek, R., Jurczyszyn, A., Lonergan, S., Ahmadi, T., Liu, Y., Wang, J., Vieyra, D., van Brummelen, E. M. J., Vanquickelberghe, V., Sitthi-Amorn, A., de Boer, C. J., Carson, R., Rodriguez-Otero, P., Bladé, J. & Moreau, P., 25 Jan 2024, In: New England journal of medicine. 390, 4, p. 301-313 13 p.
Research output: Contribution to journal › Article › Academic › peer-review
All publications

Inger Nijhof

Specialization

Focus of research

Assessing frailty in myeloma: The pursuit of simplicity may sacrifice precision of predicting clinical outcomes

Additional booster doses in patients with chronic lymphocytic leukemia induce humoral and cellular immune responses to SARS-CoV-2 similar to natural infection regardless ongoing treatments: A study by ERIC, the European Research Initiative on CLL

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.

We use cookies